• Explore /
  • Poster
  • / Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.

Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.

Abstract Poster

Authors

Angeles Secord

Angeles Alvarez Secord

Duke Cancer Institute, Duke University Medical Center, Durham, NC

Angeles Alvarez Secord , David Tritchler , Yingmiao Liu , Mark D. Starr , John C. Brady , Heather A. Lankes , Herbert Hurwitz , Robert S. Mannel , Krishnansu Sujata Tewari , David M. O'Malley , Heidi J. Gray , Jamie Nadine Bakkum-Gamez , Keiichi Fujiwara , Matthew Boente , Wei Deng , Robert Allen Burger , Michael J. Birrer , Andrew B. Nixon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Citation

J Clin Oncol 34, 2016 (suppl; abstr 5521)

DOI

10.1200/JCO.2016.34.15_suppl.5521

Abstract #

5521

Poster Bd #

344

Abstract Disclosures

Similar Posters

First Author: Susan Halabi

First Author: Xieqiao Yan

First Author: Panagiotis J. Vlachostergios

First Author: Yingmiao Liu